Brief Report| Volume 23, ISSUE 10, P762-764, October 2017

Accepting Hearts From Hepatitis C–Positive Donor: Can We Expand the Donor Pool?



      Until recently, transplantation from hepatitis C–positive donors was relatively contraindicated as eradication of active hepatitis C previously required an interferon-based regimen that has been associated with rejection in solid organ transplantation. New interferon-free treatment regimens for hepatitis C have fewer adverse events and higher cure rates than interferon-based regimens. Interferon-free regimens have been shown to be safe in the liver transplantation literature, but little is known about the safety and efficacy of treatment in heart transplantation.

      Case Description and Discussion

      Here we report a case of successful eradication of hepatitis C with a non–interferon-based regimen using ledipasvir-sofosbuvir following combined orthotopic heart and liver transplantation. Based on the prevalence of hepatitis C in the general population, inclusion of hepatitis C–positive donors for heart transplantation can expand this component of the donor pool 3- to 6-fold.


      In carefully selected patients and recipients, inclusion of hepatitis C–positive donors may allow for expansion of the donor pool.

      Key Words

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Journal of Cardiac Failure
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


      1. United Network for Organ Sharing based on OPTN data as of July 29, 2016.
        (Available at:) (Accessed August 8, 2016)
        • Lavanchy D.
        Evolving epidemiology of hepatitis C virus.
        Clin Microbiol Infect. 2011; 17: 107-115
        • Alter M.J.
        • Kruszon-Moran D.
        • Nainan O.V.
        • McQuillan G.M.
        • Gao F.
        • Moyer L.A.
        • et al.
        The prevalence of hepatitis C virus infection in the United States, 1988 through 1994.
        N Engl J Med. 1999; 341: 556-562
      2. United Network for Organ Sharing based on OPTN data as of April 28, 2017.
        (Accessed May 1, 2017)
        • Aljumah A.A.
        • Saeed M.A.
        • Al Flaiw A.I.
        • Traif I.
        • Al Alwan A.M.
        • Al Qurashi S.H.
        • et al.
        Efficacy and safety of treatment of hepatitis C virus infection in renal transplant recipients.
        World J Gastroenterol. 2012; 18: 55-63
        • Sanai F.M.
        • Mousa D.
        • Al-Mdani A.
        • Al-Shoail G.
        • Al-Ashgar H.
        • Al Meshari K.
        • et al.
        Safety and efficacy of peginterferon-α2a plus ribavirin treatment in renal transplant recipients with chronic hepatitis C.
        J Hepatol. 2013; 58: 1096-1103
        • Wang B.Y.
        • Chang H.H.
        • Chen I.M.
        • Shih C.C.
        • Yang A.H.
        Peginterferon alpha-2b and acute allograft failure in a heart transplant recipient.
        Ann Thorac Surg. 2010; 89: 1645-1647
        • Afdhal N.
        • Zeuzem S.
        • Kwo P.
        • Chojkier M.
        • Gitlin N.
        • Puoti M.
        • et al.
        Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection.
        N Engl J Med. 2014; 370: 1889-1898